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ABSTRACT This review presents seven national asthma programmes to support the European Asthma
Research and Innovation Partnership in developing strategies to reduce asthma mortality and morbidity
across Europe. From published data it appears that in order to influence asthma care, national/regional
asthma programmes are more effective than conventional treatment guidelines. An asthma programme
should start with the universal commitments of stakeholders at all levels and the programme has to be
endorsed by political and governmental bodies. When the national problems have been identified, the
goals of the programme have to be clearly defined with measures to evaluate progress. An action plan has
to be developed, including defined re-allocation of patients and existing resources, if necessary, between
primary care and specialised healthcare units or hospital centres. Patients should be involved in guided
self-management education and structured follow-up in relation to disease severity. The three evaluated
programmes show that, thanks to rigorous efforts, it is possible to improve patients’ quality of life and
reduce hospitalisation, asthma mortality, sick leave and disability pensions. The direct and indirect costs,
both for the individual patient and for society, can be significantly reduced. The results can form the basis
for development of further programme activities in Europe.
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Introduction
In Europe, almost 10 billion people <45 years of age have asthma [1]. The prevalence of asthma in the
European Union (EU) is 8.2% in adults and 9.4% in children.
In 2013, the World Health Organization (WHO) estimated that every year 25 billion disability-adjusted life
years (DALYs) are lost because of asthma [2]; of this, 5.2 billion DALYs are lost within the EU [1].
Asthma is the most common noncommunicable disease among children [3]. In the majority of cases
asthma is mild, but severe asthma occurs in 10–20% of patients [4]. The direct and indirect costs of
asthma to societies are substantial [5]. Recent calculations estimate direct costs within the EU to be nearly
€20 billion, indirect costs to be €14 billion and a monetised value of DALYs lost to be €38 billion, which
totals €72 billion [6].
Together, the increasing prevalence of asthma, its costly burdens on European societies and the persistent
gaps in asthma research have provided the rationale for the European Asthma Research and Innovation
Partnership (EARIP). EARIP, supported by the 7th Framework Programme of the European Commission,
has been prioritised by the EU to unite Europe with a common asthma research agenda for the next
decade. Additionally, it aims to build on and harmonise existing individual asthma activities, in order to
generate interconnectivity in asthma management and develop a comprehensive and focused approach to
reduce asthma-related mortality and morbidity across Europe, catalysing societal gains by directly linking
research to public breakthroughs. The present overview of European national asthma programmes ensures
that EARIP identifies current best practices and integrates them into new recommendations for research
and innovation needs. It will be of key importance for EARIP’s discussions of health and care system
change to help identify processes that have truly improved outcomes and been effective at keeping patients
at the centre of asthma management and treatment. Promotion of such practices can help EARIP to cut
asthma deaths in Europe, reduce hospitalisations and increase optimal self-management.
In Finland between 1994 and 2004, a structured national asthma programme resulted in significant
reductions in asthma morbidity, hospital admissions, disability pensions and costs [7, 8]. This was
achieved with: earlier diagnosis and active treatment (inhaled corticosteroids as first-line therapy);
implementation of simple guidelines; organisation of collaboration between primary care and specialists;
development of local asthma physician, nurse and pharmacist networks; and patient-centred asthma
education and empowerment (guided self-management).
National asthma programmes somewhat analogous to the Finnish one have been initiated in other
European countries, including: France [9], Ireland [10, 11], Italy [12], the Netherlands [13], Poland [14–
16], Portugal [17, 18] and Turkey [19–24]. The Norwegian government issued a national asthma
programme in 2008–2012, but it is only available in the local language [25]. Additional programmes in
other local languages probably exist although they are not internationally recognised. A nationwide registry
for severe asthma was established in Belgium in 2009 [26].
Successful results of national asthma programmes outside Europe have been reported from Australia [27, 28],
Canada [29, 30], Singapore [31], Brazil [32], Costa Rica [33] and Tonga [34].
Asthma guidelines are valuable but useless if they are poorly implemented and too complex for adoption
by primary care physicians [35–38]. The Global Initiative for Asthma (GINA) has clearly seen
implementation as the most urgent priority if progress is to be made in addressing asthma care through
guidelines [38]. Initiatives aiming to improve asthma care need to be well-planned and coordinated. It is
an advantage if they are initiated or supported by governmental bodies [39, 40]. The positive results of
published coordinated activities, such as in Finland, together with the increased burden of the disease,
have called for integral involvement of policymakers and healthcare officials [41, 42].
The Global Asthma Network (GAN) is an organisation that includes asthma centres in more than 100
countries (28 in Europe) (www.globalasthmanetwork.org). GAN follows up the achievements of the
International Studies on Asthma and Allergy in Childhood (ISAAC) programme 1991–2012 [43–46]. In
2011, GAN reported that >60% of the participating countries had their own asthma guidelines for adults
and children. In addition, international guidelines for adult and childhood asthma were used in 10% and
12% of the countries, respectively.
The results of clinical surveys, such as the GAN 2011 report [47], have resulted in important initiatives at
the political level. In 2011, the European Council recognised asthma as the most common, chronic
noncommunicable disease of childhood. The council recommended its member states to initiate
programmes with integrated prevention, early diagnosis and treatment, through cooperation with relevant
stakeholders, especially patient and health professional organisations [48, 49]. “A community problem
needs community solutions” [7]: all healthcare professionals should collaborate and agree about the
structural changes necessary to improve management.
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Definitions
Asthma programme
A well-described activity planned to influence a defined burden of asthma within a nation or region, with
defined time lines and goals and with a structured implementation plan to achieve the goals. A
programme also includes the description of necessary resources and their possible re-allocation, and a
defined follow-up plan and presentation of results.
Asthma guideline
A document developed by international or national/regional experts in order to best describe optimal
management and treatment of asthma.
Asthma action plan
A description of how an individual patient should manage asthma, including advice for changes in
medication, if necessary, and a plan for contact with the healthcare system.
Aims
The activities of EARIP aim to reduce asthma mortality in Europe by 25% within 10 years and by 50%
within 20 years. The partnership, made up of 12 European-based organisations, also aims to halve hospital
admissions rates, speed up the discovery of new treatments and improve self-management. In order to
form an updated platform for achieving the goals, the European Federation of Allergy and Airways
Diseases Patients’ Association (EFA), within the framework of the EARIP project, initiated a systematic
review of European national and regional asthma programmes.
To achieve these goals, one starting point is to identify the steps and procedures within those published
programmes that have resulted in measurable effects. Thereby key requirements are identified for
replication programmes in different national contexts.
Methods
We identified publications on national and regional initiatives that aimed to improve quality of asthma
care in a large population. Articles were selected when they presented clear goals and measurable results of
such interventions.
The terminology related to asthma programmes, plans, guidelines and strategies is confusing [50]. In this
review, we define an asthma programme as an activity with: defined time frames; identified management
and treatment problems; clear goals for planned activities; definition and implementation of strategies to
achieve the goals; and results of the interventions.
A systematic search was conducted in PubMed, the Cochrane Database of Systemic Reviews, EMBASE,
Web of Science and the Science Citation Index using the following specific keywords: “asthma plan”;
“national asthma plan”; “asthma programme”; “asthma program”; “national asthma programme”; “national
asthma program”; “asthma health care plan”; “POLASTMA”; “Programme for Control of Asthma and
Allergic Rhinitis (ProAR)”; “Finnish asthma programme”; “asthma health promotion”; “asthma
education”; “asthma cost effectiveness”; “national asthma agenda”; “national asthma project”; “national
asthma strategy”; and “national asthma policy”.
A total of 12531 citations were screened based on the title and topic; 732 potentially relevant articles
were identified for further evaluation. The excluded group consisted mostly of publications on individual
patient asthma plans, comparisons of different treatment strategies, genetic studies, research programmes
with no intervention component and programmes conducted on small groups of people. After
processing the initial results and excluding all duplicates, the remaining 412 article abstracts were
evaluated for inclusion, obtaining the full text where necessary. Finally, 147 articles were chosen that we
found relevant for review. Out of these, a total of 53 publications referred to national asthma
programmes and 19 were European, of which eight specifically referred to the national asthma
programme in Finland. There were 68 regional programmes, mostly from the USA, and only two from
Europe. In addition, other national programmes were identified via the Global Alliance against Chronic
Respiratory Diseases (GARD) documents, reference lists of published papers and press releases. The
Asthma Health Outcomes Project (AHOP) in the USA was also reviewed as it had identified 532
activities related to asthma in 30 countries and 46 US states, including qualitative data from 223
so-called asthma programmes [51].
Results
Identified national asthma programmes in Europe are listed in table 1. More details about the programmes
and their results are summarised in the tables E1 and E2. The first European National Asthma Programme
476 DOI: 10.1183/16000617.00008114
ASTHMA AND ALLERGY | O. SELROOS ET AL.
was the Finnish 10-year programme (1994–2004), which has been the model for other European and
non-European programmes. Results and several follow-up reports of the Finnish programme have been
published previously [52–59]. Apart from the Finnish programme, results have only been published from
the Polish [14, 15] and Portuguese [17] programmes. The other listed programmes have started recently
and results are not yet available.
Finnish programme
The programme in Finland began because the prevalence of asthma and societal burden of the disease was
increasing in the 1980s and 1990s. Asthma was the third most common chronic disorder requiring
long-term medication after hypertension and coronary heart disease. The number of new cases, calculated
from the number of patients entitled to special reimbursement for prescriptions of anti-asthma drugs,
increased from 1986 to 1995, and increased most rapidly among children and adolescents. In 1995,
approximately 150000 patients (table E1), ∼3% of the population, received special drug reimbursement
based on physician-diagnosed asthma and the need for regular maintenance medication. The majority of
the patients (60%) suffered from mild asthma, 20% from moderate asthma and 20% from severe asthma
[39]. In the early 1990s, the overall annual costs of asthma were estimated at US$600 billion. This
included direct costs for medical care and indirect costs related to disabilities and loss of production. The
costs of severe asthma accounted for ∼60% of the total costs. The main achievements of the Finnish
Asthma programme are shown in the tables E1 and E2, and these align closely with the ambitions for
EARIP.
During the programme period there was a continuous growth in the number of asthma patients entitled to
special reimbursement for their drug costs (mainly due to increase of patients receiving proper treatment)
(fig. 1). Simultaneously, the burden of asthma started to decrease, e.g. the number of asthma-related
hospital days fell by 54%.
Since the end of the programme in 2004, the positive development has continued. A 24-year follow-up
demonstrated that the number of patients with persistent asthma in the national health insurance registry
tripled [56] (unpublished observation). In these people, asthma control was improved and, disability
pensions and sickness allowances decreased further. The total annual asthma-related costs fell by 32%,
from €287 billion to €196 billion. The major cost saver was a decrease in indirect costs driven by disability
pensions. However, annual direct healthcare costs increased by 28%, from €82 billion to €105 billion due
to increased use of drugs. Overall, annual costs per patient decreased by 75%, a fall from €3452 to €834.
The annual theoretical total cost savings during the year 2010, compared to predicted, were at least
€300 billion.
In a follow-up study of the Finnish programme from 2000 to 2010, although the total number of hospital days
continued to fall, a relative increase was found in patients aged >65 years, and particularly in females [58].
TABLE 1 National and regional asthma programmes identified in Europe
Country [Ref.] Study period Initiator Executor
National
Finland [7, 8] 1994–2004 Finnish Ministry of Social Affairs
and Health and Working group
Finnish Lung Health organisation,
a nongovernmental organisation
France [9] 2002–2005 National Agency for Accreditation
and Evaluation of Health on
behalf of the French National
Health Executive
Eight medical specialist societies
Ireland [10, 11] 2014–2017 Health Service Executives Asthma Society of Ireland
Italy [12] 2013 Global Alliance against Chronic
Respiratory Diseases
42 partners
The Netherlands [13] 2014–2018 Lung Alliance Netherlands
Poland [16] 2009–ongoing Polish Society of Allergology
Portugal [18] 2000–2011; 2012–2016 Directorate General of Health
Portuguese Ministry of Health
Directorate General of Health
Turkey [20, 42] 2008–ongoing Turkish Ministry of Health Turkish Respiratory Society
Regional
Poland [14] 2000–2003 Dept of International Medicine
Asthma and Allergy, Bazlicki
University Hospital, Lodz
Lodz Regional Health Insurance
Fund (sponsor)
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Results from the follow-up study showed costs for asthma totalling €206 billion, the majority of which was
made up of the cost of drugs (€108 billion) and primary care visits (€63 billion). The changes during the
period 2000–2011 were a reduction in costs of visits to the doctor (€59–€43 billion), rehabilitation (€5–
€2 billion) and disability pensions (€60–€22 billion) [55]. The real costs in relation to expected costs if no
programme had been implemented are presented in figure 2.
A recent study performed in Finnish pharmacies showed that a change in asthma severity has
occurred in the country as the number of severe asthmatics has dropped from 10% (in 2000) to 4%
(in 2010) [60]. In 1987, only one-third of all patients with asthma used controller medication [8], but
in 2004 85% of the patients already used inhaled corticosteroids on a daily basis [58]. This change in
use of controller medication implies better asthma control at a population level.
Achievements in other countries
The results of the regional programme in 2000–2003 in the Lodz area of Poland also showed a decrease in
hospital days, length of hospitalisation and overall asthma costs despite an increase in number of patients
(table E2) [14, 15]. The Portuguese national programme in 2000–2007 showed a 15% reduction in
hospitalisation rate (table E2) [17].
In Spain, several regional programmes have been initiated since 1992. In northwest Spain, hospital
admissions due to childhood asthma decreased from 2.91 per 1000 inhabitants in 1995 to 1.33 per
1000 inhabitants in 2007 [61]. In France admissions decreased from 10.8 per 10000 inhabitants in 1998 to
8.6 per 10000 inhabitants in 2002 in patients aged ⩾10 years [62]. The admission rate has further
decreased since the implementation of the National Asthma Programme (fig. 3).
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FIGURE 2 Realised annual expenditures of asthma care and theoretical annual costs where an increased prevalence of
asthma is observed, but care practices remain at the 1987 level. Reproduced and modified from [55] with permission
from the publisher.
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During the past two decades (1990–2008), the prevalence of asthma-related symptoms in the Swedish
population aged 20–44 years has remained unchanged at 7% [63]. In Sweden, Denmark and Norway,
national asthma treatment guidelines have been published [64–66] and implemented; in particular, the
early use of inhaled corticosteroids has been widely accepted. A recent random population survey reported
the use of asthma drugs in Sweden in 2010 compared with 1992 [67]. A five-fold increase in the use of
inhaled corticosteroids was noted since 1990, from 1.5% to 7.7% of the population, and a decrease in the
use of short-acting β2-agonists was reported. As mentioned previously, this change in use of asthma
medication may imply better asthma control and corroborates the increase in use of inhaled corticosteroids
in Finland [7, 8]. In a multinational study based on the European Community Respiratory Health Survey
series of patients (including 12 European countries), a positive change in asthma-related outcomes was
noticed in parallel with an increase in the use of inhaled corticosteroids [68]. Asthma-related mortality in
Europe has also significantly decreased, from 6287 deaths in 1985 to 1164 in 2012 (−80%) [69]. This
shows that good results can also be achieved without formal national asthma programmes, as long as
evidence-based guidelines are implemented and widely used.
Discussion
In many countries and regions, physicians and professional organisations devoted to the care of patients with
asthma have adopted international asthma guidelines and developed regional or local versions and clinical
routines. These activities have been associated with improvements in the management and control of
individual patients’ asthma [70, 71]. At the same time, the importance of patient involvement in their
treatment has become evident as strategies for guided self-management have been developed and gradually
improved. In the mid-1990s, early randomised studies showed that guided self-management with patients’
own adjustment of anti-inflammatory medication based on symptoms and home peak flow measurements
reduced exacerbations and other asthma events compared with traditional therapy [72]. This also resulted in
reduced asthma care costs [73]. A systematic review of 36 trials found guided self-management of asthma in
adults to be clearly advantageous compared with usual care and to significantly improve patients’ health [74].
This systematic review of national and/or regional asthma programmes within Europe shows that during
recent years several important initiatives have been undertaken. Several activities have been started within
the GARD programme, together with activities against other chronic respiratory diseases [41, 42]. The
management and treatment recommendations have been based on international asthma guidelines [4].
However, so far, only a few results based on programme experiences have been published. Only results
from a regional programme in Poland [14, 15], and national programmes in Portugal [17] and Turkey
[42] have been published in addition to the 17-year results of the Finnish programme [58]. An
achievement with all programmes has been a clear reduction in asthma-caused hospitalisation rates.
However, small steps towards improved asthma care have also been taken in other European countries. In
Romania, “World day of COPD” in 2010–2012, including asthma, resulted in a three-fold increase in the
number of new cases with a diagnosis of asthma [75]. In the Czech Republic, GARD leaders launched
CARO (Czech Alliance against Chronic Respiratory Diseases) in 2007. In collaboration with 21 other
stakeholders (national scientific, academic, professional and patients’ organisations), they have planned
coordinated activities against chronic respiratory diseases, including asthma [42]. Over the past 2 years,
national programmes have also been initiated in Ireland [11], Italy [12] and the Netherlands [42].
FIGURE 3 Hospital admission rates in
France during implementation of the
National Asthma Programme. Data
from the Agence Technique de
l’Information sur l’Hospitalisation.
8
9
■
■
■ ■
■
■
■
■
■ ■ ■ ■ ■ ■
■
■
◆◆◆
◆◆◆
◆◆◆
◆
◆
◆
◆◆
◆
◆
7
5
6
4
3
2
Females
Males
1
0
H
os
pi
ta
l a
dm
is
si
on
 r
at
e 
pe
r 
10
 0
00
Year
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
DOI: 10.1183/16000617.00008114 479
ASTHMA AND ALLERGY | O. SELROOS ET AL.
In order to better understand what makes asthma programmes successful, AHOP gives some important
information [51]. A total of 427 national and international activities were reviewed and a range of factors
were identified that were associated with positive outcomes. The observations suggested that the first
decision of programme implementers should be to determine the outcome(s) on which they wish to have
an impact. If the goal is to reduce healthcare use, then data suggested that attention should be paid to its
relationships with clinical care providers, community-based organisations and relevant governmental bodies.
If the goal is to improve medication use, collaboration is especially important because it is likely to enhance
access to and appreciation of asthma therapies [51]. The key issues associated with successful programmes
were community centeredness, clinical connectivity, collaboration and responsiveness to needs.
National asthma programmes should be built on evidence-based guidelines developed by expert
organisations, with input from primary care and patient groups. However, if guidelines are too detailed
and complicated, they may be poorly implemented. There are several barriers to overcome in order for
guidelines to be used in every day clinical practice. The problems may not only be in the content of
guidelines, but also the to local behaviour and habits of physicians and patients [36–38]. Even the best
guidelines are useless if they are not widely and successfully promoted and implemented [76].
The lessons to be learnt from national asthma programmes are also presented in figure 4. Programme
development should be based on evidence and practical knowledge. The planning and implementation of
the programme needs broad commitments from healthcare professionals and governmental bodies and
other stakeholders. The working group/society developing the programme development must realise that a
prospective action plan is required. Depending on the situation in the country/region, the goals, which are
preferably quantitative, can be divided into several steps, but every goal has to be well defined. The
follow-up activities, including presentation of results, should also be expressly outlined at the outset.
Official registers should be effectively developed and employed.
This review has shown that successful asthma programmes have the following clinical characteristics: 1)
improving early diagnosis and introduction of first-line treatment with anti-inflammatory medication
(mainly inhaled corticosteroids); 2) improving long-term disease control; 3) introducing simple means for
guided self-management to proactively prevent exacerbations or attacks; and 4) effective education and
networking with general practitioners, nurses and pharmacists. A systematic approach is needed with
emphasis placed on motivation and organisation. Improvements can be achieved by relatively simple
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FIGURE 4 Flow chart of strategic planning, implementation and evaluation of the programme. GP: general practitioner; ICS: inhaled corticosteroid; NGO:
non-governmental organisation. Reproduced and modified from [7] with permission from the publisher.
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means. All the main stakeholders should be represented when multidisciplinary actions are planned. The
involvement of nongovernmental organisations and patient organisations is especially important, as these
groups are aware of the grass-root problems and enable patient and family commitment. Any programme
should set three to five goals, preferably numerical, and for each goal, specific targets (what to do), tools
(how to do it) and outcomes (what to follow and measure) should be defined.
All the experience from the national and local interventions converges, regardless of the healthcare system
and its coverage. A major change for the better can be achieved by local efforts, systematic planning and
networking to implement best asthma practices. The gain is remarkable, both in reducing human suffering
as well as societal costs. The asthma burden can be tackled, and it is the responsibility of asthma experts
and healthcare professionals to collaborate with national public health authorities, patient organisations
and international organisations for better efficiency, management and care.
There is a bias with this review. The search was restricted to published data and many national
programmes were probably not found. There is also a number of limitations when interpreting the results
of the published asthma programmes. First, there are few little data to compare the interventions in
different countries or areas. Because real-life large populations are included, no control groups exist.
Comparable data is also lacking in terms of planning, organisation and implementation activities. It must
be recognised that efforts and time given to the programmes, and the willingness within the healthcare
system to accept proposed changes, have had an impact on their success (e.g. the Finnish programme).
Secondly, when programmes are running for a long period of time, it cannot be ignored that changes have
occurred in management principles for other reasons apart from the programme. Maybe the physicians’
behaviour has changed in terms of criteria for inpatient admission. The possibility to hospitalise a patient
may also be influenced by administrative changes in the healthcare system resulting in reduced availability
of hospital beds. The overall picture of asthma may also change as more patients with mild disease have
been diagnosed and this will be reflected in the calculations of costs per patient.
Nevertheless, this review shows that clear improvements have been seen in asthma care in countries where
asthma programmes have been initiated. It is also obvious that asthma mortality has declined although it
cannot be claimed that the main reason behind this change would be the access to specific asthma
programmes. The awareness of asthma guidelines has certainly also played a role, as shown by the
Scandinavian experiences [63, 67]. Despite all these limitations, the present review can contribute to
rational initiatives and activities as planned within EARIP.
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